A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
Study sponsor: Novavax
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-07-25Actual
Enrollment · participants1579Actual
Source updated2024-07-16Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.